Evidence map›Paper›PMID 29446731›Full record

ReviewCurrent medicinal chemistry2018

Vitamin D Receptor: A Novel Therapeutic Target for Kidney Diseases.

Shikun Yang, Aimei Li, JianWen Wang, Jun Liu, Yachun Han, Wei Zhang, Yan Chun Li, Hao Zhang

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05298163 (Effects of Calcitriol on Podocytes in Diabetic Kidney Disease Patients), which is not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05298163 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Effects of Calcitriol on Podocytes in Diabetic Kidney Disease Patients: Assessment of Urine Podocin, Urine Nephrin, Urine Interleukin-6, Urine KIM-1, Plasma Renin, and Albuminuria

TypeinterventionalSponsorIndonesia UniversityRan2022 to 2022Enrolled120ConditionsDiabetic Kidney DiseaseArmsCalcitriol capsules, Placebo
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Vitamin D and Brain Health.Advances in experimental medicine and biology · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Impact of vitamin D and vitamin D receptor activator in diabetic nephropathy.Frontiers in clinical diabetes and healthcare · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shikun YangDepartment of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Aimei LiDepartment of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
JianWen WangDepartment of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jun LiuDepartment of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yachun HanDepartment of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wei ZhangDepartment of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yan Chun LiDepartment of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hao ZhangDepartment of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Central South University · CNThird Xiangya Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKidney disease is a serious problem that adversely affects human health, but critical knowledge is lacking on how to effectively treat established chronic kidney disease. Mounting evidence from animal and clinical studies has suggested that Vitamin D Receptor (VDR) activation has beneficial effects on various renal diseases.

methodsA structured search of published research literature regarding VDR structure and function, VDR in various renal diseases (e.g., IgA nephropathy, idiopathic nephrotic syndrome, renal cell carcinoma, diabetic nephropathy, lupus nephritis) and therapies targeting VDR was performed for several databases.

resultIncluded in this study are the results from 177 published research articles. Evidence from these papers indicates that VDR activation is involved in the protection against renal injury in kidney diseases by a variety of mechanisms, including suppression of RAS activation, anti-inflammation, inhibiting renal fibrogenesis, restoring mitochondrial function, suppression of autoimmunity and renal cell apoptosis.

conclusionVDR offers an attractive druggable target for renal diseases. Increasing our understanding of VDR in the kidney is a fertile area of research and may provide effective weapons in the fight against kidney diseases.

Indexed as

AnimalsAnti-Inflammatory AgentsHumansKidney DiseasesReceptors, CalcitriolAnti-Inflammatory AgentsReceptors, CalcitriolAcute kidney injurychronic kidney diseaserenal injuryrenal osteodystrophyrenal tubular epithelial cell.Vitamin D receptor

Identifiers

PMID29446731
PMCPMC6142412
OpenAlexW2785987159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.